Reflective analysis on the current 131I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2025-07 · 52 (9) · 3125-3134
DOI: 10.1007/s00259-025-07153-x ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 08.03.2025. Verfasst von Yuqing Sun und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of M…. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine Radioisotopes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, Cancer Foundation of China, Health Commission of Guangxi Zhuang Autonomous Region.
Abstract (Originalsprache)
PURPOSE: Radioiodine (131I) adjuvant therapy (RAT) is given to treat subclinical tumor of differentiated thyroid cancer (DTC) that may or may not actually be present after prior adequate treatment, yet the indications and benefits for RAT remain controversial. This multi-center study retrospectively evaluated the real targets and responses to RAT in intermediate- and high-risk patients, aiming to refine current "one-size-fits-all" guidelines. METHODS: Totally 599 intermediate- and high-risk DTC patients from three centers were enrolled. The post-operative disease status, instant purpose verification and 12-month response to RAT were assessed using thyroglobulin levels, imagings and post-therapy whole-body scan (Rx-WBS) during follow-ups. RESULTS: Totally 49.75% patients were assessed as post-operative disease status excellent response (ER)/indeterminate response (IDR), 37.56% patients were biochemical incomplete response (BIR) and 12.69% were structural incomplete response (SIR). Through instant purpose verification, 49.92%, 36.73%, and 13.36% patients were targeted at remnant thyroid, biochemical and structural/functional disease, respectively. 59.39%, 13.48%, 16.55%, and 10.58% patients were ER, IDR, BIR and SIR at 12-month final response, respectively. 95.64% patients with post-operative ER/IDR remained 12-month ER/IDR. 45.78% post-operative BIR converted to ER/IDR. Intermediaterisk, T1/T2 staging, non-thyroid capsule invasion, non-multifocal lesion, times of surgery, no abnormal finding on Rx-WBS were predictors for post-operative BIR transferred to 12-month ER/IDR (all P 3.7 GBq, median 5.55 GBq, IQR 4.625 GBq-5.55 GBq), especially in those with less aggressive clinicopathological features who may even obtain ER/IDR at 12-month response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking, China.
- Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking, China.
- Department of Nuclear Medicine, Affiliated Hospital of Guilin Medical University, Guilin, China.
- Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China.
- Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking, China. linyans…
- Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking, China. linyansong1968@163.com.
ORCID-Profile: Yan-Song Lin
Förderung
- National High Level Hospital Clinical Research Funding
- Cancer Foundation of China
- Health Commission of Guangxi Zhuang Autonomous Region
Zitieren
APA
Sun, Y., Zhao, Y., Sun, D., Mu, X., Li, J., Lu, C., Lu, L., Lin, C., Lv, J., Li, R., Wang, X., Pan, Y., Cheng, W., Lin, Y. S., & Fu, W. (2025). Reflective analysis on the current 131I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 52(9), 3125-3134. https://doi.org/10.1007/s00259-025-07153-x
Vancouver
Sun Y, Zhao Y, Sun D, Mu X, Li J, Lu C, et al. Reflective analysis on the current 131I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(9):3125-3134. doi:10.1007/s00259-025-07153-x
BibTeX
@article{Sun2025,
author = {Sun, Yuqing and Zhao, Yihan and Sun, Di and Mu, Xingyu and Li, Jiao and Lu, Chenghui and Lu, Lu and Lin, Chunhao and Lv, Jinfu and Li, Ruochen and Wang, Xufu and Pan, Yijin and Cheng, Wuying and Lin, Yan-Song and Fu, Wei},
title = {Reflective analysis on the current 131I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {9},
pages = {3125--3134},
doi = {10.1007/s00259-025-07153-x}
}
EUVIMED